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New Findings: 
1. What is the central question of this study? 
Can media conditioned by ex vivo human serum regulate muscle protein synthesis in skeletal 
muscle cells in vitro? 
2. What is the main finding and its importance? 
This study demonstrates that media conditioned by ex vivo human serum can regulate 
muscle protein synthesis in skeletal muscle cells in vitro via the mTOR pathway, and this can 
be differentially regulated by fed and fasted ex vivo human serum. 
Abstract:  
Human serum embodies the integrated systemic response to any condition or perturbation which may 
regulate muscle protein synthesis (MPS). Conditioning of media with human serum represents a 
physiologically relevant method of regulating MPS in vitro. The primary purpose of this study is the 
development of a model using ex vivo human serum to condition media and regulate MPS in in 
vitro skeletal muscle cells. Four young healthy males reported to the lab after overnight fast 
and were fed with 0.33g.kg
-1
 BM whey protein. Blood samples were taken prior (Fasted) and 
60 min postprandial (Fed).   Fully differentiated C2C12s were nutrient and serum deprived 
for 1 h and subsequently treated with media conditioned with Fasted or Fed ex vivo human 
serum (20%) for 4 h. MPS was measured using SUnSET and activation of mTOR, P70S6K 
and 4EBP1 by western blot. Fasted and fed ex vivo human serum increased MPS (p<0.05). 
Though a strong effect (ƞ2=0.36) for increased MPS in Fed relative to Fasted was observed, 
this was not statistically significant (p>0.05). Activation of mTOR, P70S6K and 4EBP1 was 
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(p<0.05). Here we developed and optimised the conditions for culture of C2C12 skeletal 
muscle cells, measurement of MPS and signalling in media conditioned by ex vivo human 
serum. Furthermore, the functionality of the model is demonstrated by comparison of the 
response to media conditioned by fasted and fed ex vivo human serum. 
1. Introduction 
Numerous studies have measured Muscle Protein Synthesis (MPS) in vivo using stable isotope tracers 




H), or nitrogen (
15
N) motifs. The 
incorporation of these labelled AAs into muscle protein allows for the calculation of a fractional 
synthetic rate (FSR) of MPS (Rennie et al., 1982; Yarasheski, Smith, Rennie, & Bier, 1992). More 
recently, 
2
H2O incorporation techniques have been used to calculate FSR in more free living 
conditions (Wilkinson et al., 2014). However, these techniques are invasive; require multiple skeletal 
muscle biopsies, analytically technically challenging, and expensive. Evidence from in vitro platforms 
offer an attractive alternative and can provide prior justification for translation to in vivo human 
experimentation.  
Classically, in vitro skeletal muscle platforms are cultured and differentiated in growth stimulating 
media such as Dulbecco’s Modified Eagle’s Media (DMEM) supplemented with animal serum. 
DMEM is a nutrient rich media, with supra-physiological concentrations of several potent regulators 
of MPS such as the Essential AAs (EAA) including leucine. Stimulating MPS in a background media 
containing DMEM with high concentrations of these regulators is likely a confounding influence. 
Thus, removal of these regulators from any background media potentially represents a better model to 
study factors affecting MPS in vitro.  
Conditioning of culture media represents a model of modulating MPS in skeletal muscle in vitro.  
Typically, this is achieved by the addition of a factor, nutrient or compound to a background media. 
Translation of this approach to the in vivo human model is potentially limited as the physiological 
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encounter is questionable. Human serum ex vivo from diverse populations and under different 
nutrition and exercised conditions represents a potential model to ‘condition’ culture medium and 
modulate MPS in vitro. This ex vivo/in vitro approach represents a potential model to study regulation 
of MPS in skeletal muscle cells. 
The primary purpose of this study is the development of a novel model using ex vivo human serum 
to condition media and regulate MPS in in vitro skeletal muscle. In order to achieve this, a 
number of secondary objectives have to be realised including the development of an 
appropriate background media, pre-conditioning of muscle cells, optimal serum concentration 
and time course of treatment in which to study MPS. Finally, to demonstrate the functionality 
of the model, postprandial ex vivo human serum following protein feeding is compared to 
fasted serum.  
2. Materials and Methods 
Ethical Approval 
The study was approved by the local ethics committee at the University of Limerick 
(EHSREC_2013_01_13) and conformed to the standards set by the Declaration of Helsinki, 
except for registration in a database. Four young healthy male participants, (23±3.6 y; 
75.9±10.1 kg, 1.77±0.06 m, 24.3±3.3 kg∙m
-2
, 16.4±3.3 % BF) agreed to participate in the 
study, gave informed written consent and completed the intervention trial.  
Study design 
Participants reported to the lab having fasted overnight (>10h). A clinical nurse inserted a cannula in 





Serum gel tubes (Sarstedt, Wexford, Ireland). Subsequently, participants consumed 
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collected at 0 min (baseline) and 60 min postprandial. Plasma was used to determine AA profile and 
humoral biomarkers whereas serum was used for cell culture experiments.  
Amino acid analysis  
Plasma AA profile was determined as  previously described using the Agilent 1200 RP-
UPLC system (Agilent Technologies, Santa Clara, CA, USA) equipped with an Agilent 1260 
binary pump and a G1367C automated liquid handling system (Power-Grant et al., 2016). 
Chemstation software (Agilent Technologies Inc.) was used for data acquisition. Separation 
of AAs was carried out using a C18 ZORBAX rapid resolution column (4.6 x 50 mm, 1.8 µm, 
Agilent Technologies Inc.) thermostated at 40˚C. Quantitative analysis was performed by the 
external standard method, using Agilent AA standard (Agilent Technologies Inc.). Standard 
AAs were measured in both unspiked and spiked pool plasma and recoveries were calculated.  
Metabolic/Humoral biomarker analysis 
Glucose plasma levels were analysed using a glucose assay colorimetric kit (STA-60, Cell 
Biolabs, Inc., CA, USA) following supplier’s instructions. Plasma levels of insulin and IGF-I 
were determined using a commercial kit (Merck Millipore). Bead readings were performed 
on a MAGPIX
TM




C2C12s obtained from Sigma-Aldrich (91031101, Sigma-Aldrich) were cultured in DMEM 
(D6429, Sigma-Aldrich), supplemented with 10% (v/v) Foetal Bovine Serum (FBS), 1% 
(v/v) penicillin/streptomycin (P0781, Sigma-Aldrich) and 1mM L-glutamine (G7513, Sigma-
Aldrich), at 5% CO2 in a humidified air atmosphere at 37 °C. At 70% confluence, cells were 
differentiated in DMEM supplemented with 2% horse serum (H1270, Sigma-Aldrich) as 
previously described (Murphy, Kiely, Jakeman, Kiely, & Carson, 2016). Prior to serum 
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MA, USA) containing 1 mM sodium pyruvate (GE Healthcare, Thermo-Fisher), 1% (v/v) 
penicillin/streptomycin solution, 1 mM L-glutamine, 6 mM D-glucose (Sigma-Aldrich), 34 
mM NaCl (Sigma-Aldrich) (pH 7.3). 
Cell Viability  
Crystal violet - Cells were seeded and differentiated in 96-well plates, and the assay was 
carried out as previously described (Navarro et al., 2014). Cells were washed with AA-free 
medium and changed to AA-free medium for 1 h. 100 µL of different concentrations of 
serum (0%, 10%, 20%, 50%, 100%) diluted in AA-free medium were added to each well for 
1-4 h. After treatment, cells were washed with 200 µL PBS/well (preheated at 37 °C), 
incubated with 50 µL/ well of 0.2% (w/v) crystal violet in 2% (v/v) ethanol for 20 min at 
room temperature, and washed 3 times with milli-Q water (300 µL/well) to remove excess 
dye. 100 µL/well of 1% (w/v) SDS were added and placed in a plate shaker for 10 min before 
reading the absorbance at 560 nm in a plate reader (Bio-Tek Synergy HT, Winooski, VT).   
Real Time-Glo
TM
 MT Cell viability Assay. Cells were seeded and differentiated in 96-well 
plates as described.  Cells were washed with AA and serum free medium and changed to AA-
free medium for 1 h. AA and serum free media conditioned by different concentrations of 
serum (0%, 10%, 20%, 50%, 100%) were added to each well. Real Time-Glo
TM
 MT Cell 
viability assay was carried out following manual’s instructions (Promega Corporation, 
Madison, USA), bioluminescence was measured to determine the number of viable cells by 
measuring the reducing potential of cells and thus metabolism.  
Muscle Protein Synthesis  
Measurement of MPS using surface sensing of translation technique (SUnSET) developed by 
Goodman et al. (Goodman et al., 2011) was optimised in C2C12 myotubes. Following 




This article is protected by copyright. All rights reserved. 
 
 
serum free medium for 0.5 - 4 h to determine the appropriate nutrient deprivation time. Cells 
were then subsequently nutrient deprived for 1 h and treated with human serum (0%, 10%, 
20%, 50%, 100%).   
Protein extraction and western blotting 
Cellular protein lysates were obtained by placing cells on ice, aspirating media and washing 
three times with cold-phosphate buffered saline (C-40232, PromoCell, Brennan & Co, 
Ireland). Lysis buffer (50 mM Trix-HCl pH 7.4, 50 mM NaF, 10 mM Na4P2O7, 100 mM 
NaCl, 5 mM EDTA 1% (v/v) triton X-100, 10 μM phenylmethanesulfonyl fluoride, 10 μM 
sodium orthovanadate, 1 μM pepstatin A and 1.5 μg aprotinin/mL). Lysates were placed on 
ice for 20 min before centrifugation at 130 g, 4 °C for 15 min.  
Protein lysates (30μg) and ladder (26625, ThermoFisher Scientific, MA, USA) were loaded 
on a 4-15% linear gradient SDS-PAGE precast gels (Mini-Protean TGX Stain-free, Bio-Rad 
456-8083). Following electrophoresis, gels were activated by UV for stain free technology 
using the UVITEC Cambridge Imaging system (UVITEC, Cambrige, UK). Total protein 
measurements were obtained by stain-free gel technology using the UVITEC imaging 
system. Whole-lane band densitometry was quantified for puromycin and total protein using 
NineAlliance UVITEC Software. Proteins were electroblotted onto a 0.2 μm nitrocellulose 
membrane using the semi-dry transfer technique (Trans-blot® Turbo
TM
 Bio-Rad). 
Membranes were blocked with TBST (0.05 % (v/v) Tween-20 in tris-buffered saline) 
containing 5% bovine serum albumin (BSA) for 1 h at room temperature. Membranes were 
washed four times with TBST and incubated with primary antibody at 4 °C overnight. All 
primary antibodies were diluted 1:1,000 in 5% BSA in TBST: mTOR, pmTOR, P70S6K, 
pP70S6K, 4EB-P1, p4EBP1, β-actin (Cell Signaling, The Netherlands) and puromycin 
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Ireland). After incubation, membranes were washed four times and incubated with secondary 
antibody green rabbit (926-32211 IRDye 800 CV goat anti-rabbit IgG, LI-COR Biosciences 
UK Ltd, UK) for all primary antibodies with the exception of puromycin that was incubated 
with goat anti-mouse IgG2a-specific (LI-COR Biosciences UK Ltd).  
Statistical analysis 
GraphPad Prism v7.03 was used for statistical analysis. Data were tested for normality (Shapiro-Wilk 
test) and homogeneity of variances (Levene’s test). One way and 2-way analysis of variance 
(ANOVA) with a Bonferroni correction for multiple comparisons was used for pooled serum and cell 
viability experiments respectively. Paired Samples T-tests were used to analyse MPS and signalling 
responses to fed and fasted ex vivo human serum (Figure 3). Level of significance was set at 95% (p < 
0.05). 
 
3. Results  
Table 1: Humoral biomarkers and AA profile of plasma samples 
Time (min) 0 60 Δ (0-60) 
Insulin (pM) 67±31 112±44 45±28 
GLP-1 (pM) 39±8 63±15 25±9 
GIP (pM) 8.3±3.3 20.8±5.7 12.5±3.6 
Growth Hormone (µg/L) 0.30±0.22 0.21±0.17 0.09±0.20 
IGF-1 (µg/L) 116±49 109±17 8±34 
Glucose (mmol/L) 3.7±0.3 3.2±0.5 0.5±06 
Leucine (µmol/L) 128±18 342±58 215±41 
Isoleucine (µmol/L) 59±10 194±39 135±29 
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Arginine (µmol/L) 79±13 117±18 38±8 
Branched Chain AA (µmol/L) 419±57 943±154 524±97 
EAA (µmol/L) 965±82 1895±208 930±134 
      *Data represents mean±SD (n=4) 
 
Differentiated myotubes were AA and serum deprived between 0.5-4h to assess MPS and signalling at 
different time points of nutrient deprivation. MPS is decreased within 30 min of nutrient deprivation 
by ~80%, activation of mTOR (~50%) and P70S6K (~95%) are significantly reduced within 30 min 
of nutrient deprivation and remain suppressed for up to 4 h, however, activation of 4E-BP1 (~75%) is 
not significantly reduced until 1 h following nutrient deprivation (data not shown). These results 
suggest that 1 h nutrient deprivation is sufficient to depress activation of the mTOR signalling 
pathway and MPS. Based on these findings, subsequent experiments were carried out following 1 h 
nutrient deprivation.   
 
Figure 1. Cell adherence and viability of C2C12 myotubes exposed to increasing concentrations 
of fasted human serum (n=4). Fully differentiated C2C12 myotubes were treated with AA and 
serum free media conditioned by different concentrations of pooled fasted serum (0%, 10%, 
20%, 50%, 100%) for 1-4 h. (A) Cell Adherence, expressed as percentage of cell viability referred 
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deprivation was measured using the Crystal Violet method. (B) Cell Viability, expressed as 
percentage of cell viability referred to the luminescence measured in control cells (2% HS-
DMEM) without nutrient deprivation was measured using Real Time-GloTM MT. Data are 
reported as Mean ± SEM. *p<0.05 
 
Differentiated myotubes were nutrient deprived for 1 h prior to carrying out cell viability assays 
using 10-100% pooled fasted human serum obtained from four healthy males (Table 1) for 0.5-4h. 
Cell adherence, as measured by the crystal violet assay, was significantly reduced after 2 h in 100% 
serum and after 4 h in 50% serum compared to the control condition (Figure 1A). Cell viability 
measured by the Real Time MT assay was significantly decreased after 1 h in the 100% and 50% 
serum conditions compared to control (Figure 1B). Treating cells with a lower serum concentration 
(10 or 20%) after 1 h nutrient deprivation led to no negative effect on cell viability (all time points; 
Figure 1A), or cell adherence (all time points; Figure 1B) compared with control. These data provide 
evidence that treatment with a lower serum concentration (10-20%) has no negative effect on cell 
viability during treatment up to 4 h, therefore, the higher serum concentration (20%) which is closer 
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Figure 2. MPS and signalling in C2C12 skeletal muscle cells treated 20% ex vivo fasted human 
serum. (n=4). Fully differentiated C2C12 myotubes were cultured in DMEM 2% HS before 
nutrient deprivation in AA and serum free media for 1 h. Cells were then treated with AA and 
serum free media conditioned by pooled fasted serum (20%) for up to 4 h. (A) MPS was 
measured by incorporation of puromycin (1 μM) incubated for the duration of the treatment. 
Phosphorylation of (B) mTOR, (C) P70S6K, (D) 4EBP1 relative to the total protein of interest was 
measured by western blot. Representative western blots of (E) Total protein and puromycin 
incorporation; (F) phosphorylated and total mTOR, P70S6K, 4EBP1 and β-Actin. Data are 
reported as Mean ± SEM. **p<0.01, ****p<0.0001 
 
Following 1 h nutrient deprivation, C2C12 cells were treated for 4 h with AA and serum free media 
(control) or media conditioned by 20% ex vivo pooled fasted serum for up to 4 h Repeated measures 
ANOVA revealed a statistically significant effect (p<0.01, F=14.65) of ex vivo human serum on MPS 
above the control condition after 2 h and a further increase after 4 h (p<0.01) of treatment (Figure 
2A). This suggests that 4 h of treatment is superior to observe a detectable change in MPS. 
Activation of mTOR, P70S6K and 4EBP1 was significantly increased after 2 h and 4 h of treatment 
with ex vivo human serum, however, activation of P70S6K was further enhanced after 4 h (Figure 2B, 
2C, 2D). These results demonstrate that ex vivo human serum can condition media to elicit a 
stimulatory effect on MPS mediated by signalling through the mTOR pathway. To activate signalling 
and stimulate MPS sufficiently, 4 h of treatment with ex vivo human serum was performed for all 









Figure 3. The effect of 20% ex vivo fasted and fed human serum on MPS and signalling in C2C12 
skeletal muscle cells (n=4) Fully differentiated C2C12 myotubes were cultured in DMEM 2% HS 
before nutrient deprivation in AA and serum free media for 1 h. Cells were then treated with AA 
and serum free media conditioned by individual  (n=4) fasted and fed (60 min postprandial 
0.33g.kg-1 BM protein) serum (20%) for 4 h. (A) MPS was measured by incorporation of 
puromycin (1 μM) incubated for the duration of the treatment. Phosphorylation of (B) mTOR, (C) 
P70S6K, (D) 4EBP1 relative to the total protein of interest was measured by western blot. 
Representative western blots of (E) Total protein and puromycin incorporation; (F) 
phosphorylated and total mTOR, P70S6K, 4EBP1 and β-Actin. Data are reported as Mean ± SEM. 
*p<0.05, #p<0.1 
 
Feeding 0.33g.kg-1 BM protein resulted in a change in the concentration of circulating AA and 
humoral regulators of MPS 60 min postprandial (Table 1). Following 1 h nutrient deprivation, C2C12 
cells were treated for 4 h with AA and serum free media (control) or media conditioned by 20% ex 
vivo fasted and 60 min postprandial (fed: 0.33g.kg-1 BM protein) serum from four healthy males. 
Responses to conditioned media are reported as fed relative to the fasting condition for each 
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condition (data not shown) confirming an effect of ex vivo human serum on MPS (as previously 
observed in Figure 2). Though a strong effect (ƞ2=0.36) for an increase in MPS for the fed serum 
relative to the fasted serum was observed, this was not statistically significant (p=0.14) (Figure 3A). 
Activation of mTOR, P70S6K and 4EBP1 was significantly increased after treatment with both fasted 
and fed ex vivo human serum (p<0.05) (data not shown, previously demonstrated in Figure 2). 
P70S6K and 4EBP1 activation were significantly enhanced (p<0.05) by fed compared to fasted serum 
with a large effect size observed for both (ƞ2=0.78; ƞ2=0.73) (Figure 3C, 3D). Though not statistically 
significant, a statistical trend was observed for increased activation of mTOR by fed compared with 
fasted serum (p=0.06) also with a large effect size (ƞ2=0.59) (Figure 3B). These results demonstrate 
that ex vivo fed and fasted human serum have the potential to differentially condition media and 
regulate MPS mediated by signalling through the mTOR pathway in skeletal muscle cells.  
4. Discussion 
The primary purpose of this study is the development of a model using ex vivo human serum 
to condition media and regulate MPS in in vitro skeletal muscle cells. In order to achieve this, 
a number of secondary objectives were realised including the development of an appropriate 
background media, the pre-conditioning of muscle cells, the optimal serum concentration and 
the time course of treatment in which to study MPS.  
In this study we developed the use of ex vivo human serum to condition media for the 
purpose of regulating MPS of skeletal muscle in vitro. A background media that does not 
independently stimulate MPS and can be appropriately conditioned to regulate MPS needed 
development. Typically cells are pre-conditioned prior to experimentation with appropriate 
media, usually serum free, to synchronise cells and transition to a phase of growth arrest. 
Classically this pre-conditioning step is 4 h or greater duration. However, information from 
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switched off within 30 min of removal from growth media in skeletal muscle. Therefore, we 
empirically tested the required duration of pre-conditioning of skeletal muscle cells in 
appropriate background media (AA and serum free DMEM ) to turn off both signalling and 
MPS. We found that MPS and signalling was sufficiently down-regulated within 1 h of pre-
conditioning and adopted this protocol for all subsequent experiments.  
To achieve the primary aim of this paper, we needed to establish the appropriate 
concentration of ex vivo serum to condition media for treatment of skeletal muscle. 
Previously, others have used ex vivo human serum in this way for other physiological 
outcomes such as myoblast proliferation and metabolic gene expression (Bruckbauer & 
Zemel, 2011; Nguyen et al., 2014) using a wide range of serum concentrations (5-25%). We 
ideally wanted to replicate the interstitial concentrations of the key nutrient and hormonal 
regulators of MPS. We (McCormack, Cooke, O'Connor, & Jakeman, 2017) demonstrated the 
interstitial concentrations of leucine and EAAs in response to a similar protein feeding 
paradigm used in this study (0.33g.kg
-1
BM protein), were approximately 70% of the plasma 
concentration. Therefore, a model which could use a serum concentration close to this was 
desirable. However, cell viability and adherence were negatively affected by high serum 
concentrations (50-100%) and were thus considered sub-optimal (Figure 1A, 1B). Cell 
viability and adherence at 10 and 20% serum were optimal, therefore, the higher serum 
concentration (20%) was selected for subsequent experimentation.  
To develop the measurement of MPS in response to ex vivo human serum treatment, the 
SUnSET technique was adopted. The time-course of treatment with ex vivo human serum and 
puromycin to observe a measurable effect had to be established. In our hands, we found little 
evidence of MPS as determined by puromycin incorporation when puromycin was incubated 
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2011). Our data demonstrate that puromycin incorporation is greater when included for the 
entirety of the treatment (up to 4 h) with ex vivo human serum. Increased puromycin 
incorporation and MPS signalling was observed following 4 h of treatment compared with 2 
h. Since it is the rate of MPS that may differ between conditions, therefore, 4 h was adopted 
for subsequent experimentation. This data demonstrates proof of principle, that treatment of 
skeletal muscle cells with an appropriate background media conditioned by ex vivo human 
serum (20%) can stimulate MPS as measured by puromycin incorporation and MPS 
activation via mTOR, P70S6K and 4EBP1. The effect of fasted ex vivo human serum on 
these processes is powerful, particularly when the concentrations of key regulators of MPS 
are at a nadir. This suggests there is opportunity to further impact these processes when key 
regulators are more abundant in the circulation. 
To demonstrate the functionality of the model, skeletal muscle cells were treated with ex vivo 
human sera containing different concentrations of key regulators of MPS manipulated by 
feeding protein (Table 1). Treatment of skeletal muscle cells with media conditioned by fed 
serum increased P70S6K and 4EBP1 activation (Figure 3C, 3D). Fed serum displayed a trend 
(p=0.06) to increase activation of mTOR relative to fasted serum with a large effect size 
(Figure 3B). This data confirms the ability of the model to detect differential responses in 
MPS signalling to media conditioned with ex vivo human serum in the fed and fasted 
conditions containing different concentrations of regulators of MPS.  Treatment of skeletal 
muscle cells with media conditioned by ex vivo fed serum had a large but not statistically 
significant effect on MPS compared with fasted serum (Figure 3A). The difference in 
concentration of the key regulators of MPS between conditions (Table 1) may not have been 
sufficient to distinguish this response. For example, the difference in Leucine as a potent 
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concentration, this difference between fed and fasted is ~40µmol/L. Rennie and colleagues 
reported that an increase of ~80µmol/L in extracellular leucine is required to increase MPS in 
vivo (Bohe, Low, Wolfe, & Rennie, 2001; Rennie, 2007), suggesting the differences reported 
here between fed and fasted are sufficient to further stimulate MPS signalling but do not 
result in a statistically measurable difference in MPS. It is also important to note the inter-
individual responses evident. For MPS, the fed serum increased MPS relative to fasted serum 
in only three out of four participants. This impacted the aggregate effect of the group, and is 
the reason that such a large effect size is not supported by a statistically significant result.  
A major strength of this ex vivo-in vitro approach is that human serum reflects the integrated systemic 
condition. Therefore, treatment of skeletal muscle with ex vivo serum may be more physiologically 
relevant and therefore potentially more likely to translate to a human model.  Culture medium can be 
conditioned accordingly to investigate the effects of different paradigms including nutrition, exercise, 
and inflammation. One of the advantages of this approach for nutrient interventions is that the key 
nutrient regulators that appear in the circulation have undergone human digestion as compared to 
enzymatic simulated gastrointestinal digestion models (Power-Grant et al., 2016). Furthermore, the 
humoral factors stimulated by feeding are also present. Therefore, the integrated effect of the nutrient 
and the physiological response to feeding is captured in the ex vivo serum sample and can elicit a 
pluripotent effect on MPS in skeletal muscle.  
A limitation of the model described here is the concentration of the serum. C2C12 cells do not tolerate 
exposure to media conditioned by high concentrations of serum over extended periods (4 h). Though 
we argue this is a more physiologically relevant model compared to direct treatment with nutrient 
formulations or supra-physiological concentrations of key regulators, the interstitial concentrations of 
key regulators of MPS observed by the muscle cell in vivo are not reached here (McCormack et al., 
2017). Therefore, the translation of findings from this model to the in vivo condition is less well 








In conclusion, this study describes the development of a model using ex vivo human serum to 
condition media and regulate MPS in in vitro skeletal muscle cells including the development 
of an appropriate background media, the pre-conditioning of muscle cells, the optimal serum 
concentration and the time course of treatment in which to study MPS. This study provides 
proof of principle that ex vivo human serum can be used to condition media to regulate MPS, 
mediated by signalling through the mTOR pathway.  
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